Available exclusively through Diax Labs, our highly sought, proprietary EZ Drop Compli is a groundbreaking panel that tests for compliance of medications commonly prescribed for cardiovascular disorder, diabetes, hypertension, hyperlipidemia and inflammatory conditions.
The History of EZ Drop Compli speaks to the immense value of having physicians at the helm. Diax Lab co-founder, Dr. Saad Alssab, himself a cardiologist, realized that a large percentage of patients were not complying with their critical prescription drug treatment plans. In his quest to protect chronic care patients from additional health issues and higher risks for blood clots, heart attacks, and cardiovascular decline associated with non-compliance, Dr. Alsaab created EZ Drop Compli and extended the test panel to include other chronic conditions, including diabetes.
America's Other Drug Problem
Non-adherence to prescription drugs has become the nation's other drug problem.
Diabetic patients who ignore or stray from their diabetes medications face a wide range of short- and long-term dangers, including death. For cardiac patients and diabetics alike, EZ Drop Compli is effective and proactive in determining whether prescription drugs are being closed as prescribed.
EZ Drop Compli tests for 31 distinct drugs that are different from the 64 analytes in our Prescription Drug Monitoring test panel. Cardiologists and general medicine doctors find this test to be highly valuable in forming and monitoring treatment plans based on the test's comprehensive look at health and identification of common conflicts. Unlike Diax Labs' pain management testing panels, this panel does not test for illicit drugs.
The trend toward value-based care is gaining momentum, and forward-thinking physicians are using EZ Drop Compli as an opportunity to be rewarded for improving their quality of patient care and reducing the effects and incidences of chronic diseases based on metrics such as reducing hospital readmissions, boosting preventative care and utilizing certified health technologies.